| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shohei Okura, Yasuhiko Deguchi, Tetsuji Cho, Yuki Kageyama, Koki Inou. Significant Weight Gain With the Administration of Lurasidone and Valproic Acid in Schizophrenia and Bipolar Disorder Patients. Cureus. vol 15. issue 11. 2023-12-19. PMID:38111448. |
significant weight gain with the administration of lurasidone and valproic acid in schizophrenia and bipolar disorder patients. |
2023-12-19 |
2023-12-21 |
Not clear |
| Shohei Okura, Yasuhiko Deguchi, Tetsuji Cho, Yuki Kageyama, Koki Inou. Significant Weight Gain With the Administration of Lurasidone and Valproic Acid in Schizophrenia and Bipolar Disorder Patients. Cureus. vol 15. issue 11. 2023-12-19. PMID:38111448. |
herein, we report two cases of schizophrenia and bipolar disorder who had a 10-kg gain in weight in six months with the administration of lurasidone and valproic acid. |
2023-12-19 |
2023-12-21 |
Not clear |
| Yu-Mei Wei, Xi-Jin Wang, Xiao-Dong Yang, Chuan-Sheng Wang, Li-Li Wang, Xiao-Ying Xu, Gui-Jun Zhao, Bin Li, Dao-Min Zhu, Qi Wu, Yi-Feng She. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World journal of psychiatry. vol 13. issue 11. 2023-12-11. PMID:38073894. |
safety and effectiveness of lurasidone in the treatment of chinese schizophrenia patients: an interim analysis of post-marketing surveillance. |
2023-12-11 |
2023-12-17 |
Not clear |
| Yu-Mei Wei, Xi-Jin Wang, Xiao-Dong Yang, Chuan-Sheng Wang, Li-Li Wang, Xiao-Ying Xu, Gui-Jun Zhao, Bin Li, Dao-Min Zhu, Qi Wu, Yi-Feng She. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World journal of psychiatry. vol 13. issue 11. 2023-12-11. PMID:38073894. |
lurasidone was licensed in china in 2019 for the treatment of adult schizophrenia in adults with a maximum dose of 80 mg/d. |
2023-12-11 |
2023-12-17 |
Not clear |
| Przemysław J Danek, Władysława A Danie. The Novel Atypical Antipsychotic Lurasidone Affects Cytochrome P450 Expression in the Liver and Peripheral Blood Lymphocytes. International journal of molecular sciences. vol 24. issue 23. 2023-12-09. PMID:38069119. |
lurasidone is a novel atypical antipsychotic drug acting on dopaminergic, serotonergic and noradrenergic receptors; it is applied for the long-term treatment of schizophrenia and depression in patients with bipolar disorders. |
2023-12-09 |
2023-12-17 |
rat |
| Zuzanna Mielczarek, Beata Trędzbor, Katarzyna Piekarska-Bugiel, Krzysztof Kryst. Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report. Postepy psychiatrii neurologii. vol 32. issue 3. 2023-11-30. PMID:38034503. |
neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report. |
2023-11-30 |
2023-12-10 |
Not clear |
| Veronica Begni, Moira Marizzoni, Kerstin Camile Creutzberg, Diana Morena Silipo, Mariusz Papp, Annamaria Cattaneo, Marco Andrea Riv. Transcriptomic analyses of rats exposed to chronic mild stress: Modulation by chronic treatment with the antipsychotic drug lurasidone. Progress in neuro-psychopharmacology & biological psychiatry. 2023-10-21. PMID:37865392. |
we have previously demonstrated that lurasidone, a multi-receptor antipsychotic drug approved for the treatment of schizophrenia and bipolar depression, can normalize the functional and molecular impairments induced by stress exposure, representing a valuable tool for the treatment of stress-induced mental illnesses. |
2023-10-21 |
2023-11-08 |
rat |
| Itaru Miura, Sho Horikoshi, Mizue Ichinose, Yuhei Suzuki, Kenya Watanab. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy. Drug design, development and therapy. vol 17. 2023-10-04. PMID:37789971. |
lurasidone for the treatment of schizophrenia: design, development, and place in therapy. |
2023-10-04 |
2023-10-07 |
Not clear |
| Itaru Miura, Sho Horikoshi, Mizue Ichinose, Yuhei Suzuki, Kenya Watanab. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy. Drug design, development and therapy. vol 17. 2023-10-04. PMID:37789971. |
this review aims to provide a comprehensive overview of the current literature on the drug design, development, and therapy of lurasidone for the treatment of schizophrenia. |
2023-10-04 |
2023-10-07 |
Not clear |
| Ya-Hsuan Wang, Chia-Yu Liu, Yu-Ning Her, Hung-Hsi Wu, Chia-Yi Yao, Tien-Yu Che. Lurasidone Successfully Reversed Clozapine-Induced Type 2 Diabetes Mellitus and Hypertriglyceridemia in a Patient With Schizophrenia. American journal of therapeutics. vol 30. issue 5. 2023-09-15. PMID:37713707. |
lurasidone successfully reversed clozapine-induced type 2 diabetes mellitus and hypertriglyceridemia in a patient with schizophrenia. |
2023-09-15 |
2023-10-07 |
Not clear |
| Martin Tarzian, Majd Soudan, Muhammed Alhajji, Mariana Ndrio, Adegbenro O Fakoy. Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy. Cureus. vol 15. issue 4. 2023-05-25. PMID:37228542. |
lurasidone for treating schizophrenia and bipolar depression: a review of its efficacy. |
2023-05-25 |
2023-08-14 |
Not clear |
| Małgorzata Janas-Kozik, Dominika Dudek, Janusz Heitzman, Barbara Remberk, Jerzy Samochowiec, Agnieszka Słopień, Adam Wichnia. Polish Psychiatric Association diagnostic and therapeutic management guidelines for patients with early-onset schizophrenia. Psychiatria polska. vol 56. issue 4. 2023-04-19. PMID:37074823. |
second-generation antipsychotic agents approved for the treatment of early-onset schizophrenia - aripiprazole, lurasidone and paliperidone - enable its effective and safe treatment. |
2023-04-19 |
2023-08-14 |
Not clear |
| Marcin Siwek, Krzysztof Wojtasik-Bakalarz, Anna Julia Krupa, Adrian Andrzej Chroba. Brexpiprazole-Pharmacologic Properties and Use in Schizophrenia and Mood Disorders. Brain sciences. vol 13. issue 3. 2023-03-29. PMID:36979208. |
its pharmacodynamic and pharmacokinetic profile (similarly to the other most recent antipsychotics, i.e., lurasidone or cariprazine) shows promise of increasing the effectiveness of schizophrenia treatment in the dimensions in which the previous antipsychotics were not sufficiently effective, including negative, depressive, or cognitive symptoms. |
2023-03-29 |
2023-08-14 |
Not clear |
| Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dude. Lurasidone Augmentation of Clozapine in Schizophrenia-Retrospective Chart Review. Brain sciences. vol 13. issue 3. 2023-03-29. PMID:36979255. |
the aim of our study was to evaluate the effectiveness of lurasidone augmentation of clozapine in treatment-resistant schizophrenia (sz) in a retrospective chart review. |
2023-03-29 |
2023-08-14 |
Not clear |
| Valerio Ricci, Gabriele Di Salvo, Giuseppe Main. Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report. International clinical psychopharmacology. 2023-02-28. PMID:36853746. |
lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. |
2023-02-28 |
2023-08-14 |
Not clear |
| Miriam Olivola, Vincenzo Arienti, Nicola Bassetti, Gianluca Giovanna, Natascia Brondin. Lurasidone Augmentation of Clozapine in Refractory Schizophrenia: A Case Series. Journal of clinical psychopharmacology. 2023-02-24. PMID:36825872. |
lurasidone augmentation of clozapine in refractory schizophrenia: a case series. |
2023-02-24 |
2023-08-14 |
Not clear |
| Austin G Armstrong, Sheldon H Preskor. Thoughts on the Value of Case Series in the Literature: An Example Using the Article on Lurasidone Augmentation of Clozapine in Refractory Schizophrenia. Journal of clinical psychopharmacology. 2023-02-23. PMID:36821468. |
thoughts on the value of case series in the literature: an example using the article on lurasidone augmentation of clozapine in refractory schizophrenia. |
2023-02-23 |
2023-08-14 |
Not clear |
| Teresa Guilera, Juan Pablo Chart Pascual, Maria Del Carmen Blasco, Pilar Calvo Estopiñán, Rubén Asensio Piernas González, Isabel Ramírez Martínez, Cristóbal Rodríguez Moyano, Rita Prieto Pérez, Irene Gabarda-Inat, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasc. Lurasidone for the treatment of schizophrenia in adult and paediatric populations. Drugs in context. vol 12. 2023-02-16. PMID:36793449. |
lurasidone for the treatment of schizophrenia in adult and paediatric populations. |
2023-02-16 |
2023-08-14 |
Not clear |
| Teresa Guilera, Juan Pablo Chart Pascual, Maria Del Carmen Blasco, Pilar Calvo Estopiñán, Rubén Asensio Piernas González, Isabel Ramírez Martínez, Cristóbal Rodríguez Moyano, Rita Prieto Pérez, Irene Gabarda-Inat, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasc. Lurasidone for the treatment of schizophrenia in adult and paediatric populations. Drugs in context. vol 12. 2023-02-16. PMID:36793449. |
current clinical guidelines recommend lurasidone as the first-line treatment in the acute and long-term management of schizophrenia in both adult and paediatric populations. |
2023-02-16 |
2023-08-14 |
Not clear |
| Kouji Fukuyama, Eishi Motomura, Motohiro Okad. Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation. International journal of molecular sciences. vol 24. issue 3. 2023-02-11. PMID:36768393. |
to date, the initially expected rapid onset of antidepressant effects-in comparison with conventional antidepressants or mood-stabilising antipsychotics-due to 5-ht7 inhibition has not been observed with lurasidone and vortioxetine; however, several clinical studies suggest that 5-ht7 inhibition likely contributes to quality of life of patients with schizophrenia and mood disorders via the improvement of cognition. |
2023-02-11 |
2023-08-14 |
Not clear |